Back to top

genomics: Archive

Ekta Bagri

Intellia Crashes 60% in a Year: How Should You Play the Stock?

NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.

REGNNegative Net Change IONSPositive Net Change NTLAPositive Net Change CRSPPositive Net Change

Mark Zinski

Two Smaller Companies Worthy of Your "Attention"

Here we highlight a small cap and a microcap with Zacks Outperform ratings.

ELTPNegative Net Change PRPONegative Net Change